BD1, page-39

Thanks for posting up the commercialisation strategy extract.

I hear some people say the SP should be 10c now, which would equate to a market cap of around 120mil. Is this realistic at this point in comparison to other companies on a similar product path that have been at this point? keen to hear thougths

What are people thoughts as to what the Market Cap should be after Clinical Evaluation? and what quarter should that end as that is not fully clear?

Once we hit marketing/ selling in H1 21 what do we think market cap should be here? Can anyone comment on similar companies that have similar products and sales scope and taken same path and what their approx market caps were?

Thanks.